Vaxcyte: The XpressCF Platform Enables the Development of Broad-Spectrum Vaccines and Overcomes the Limitations of Traditional Cell-Based Approaches

VAX-31 and VAX-24 are the key value drivers of Vaxcyte. They target invasive pneumococcal disease (IPD) and offer better coverage compared to competitors. Phase 1/2 results of VAX-31 showed a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025. Market potential is driven by a $13.3 billion TAM in the pneumococcal vaccine market, with potential FDA approval by the end of 2026 or 2027. Vaxcyte (NASDAQ: PCVX) is developing next-generation vaccines to prevent and treat bacterial infections...